Citarinostat
Citarinostat (ACY241) is a second generation potent, orally active and high-selective HDAC6 inhibitor with an IC50 of 2.6 nM (IC50s of 35 nM, 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 and HDAC8, respectively) . Citarinostat has anticancer effects[1].
Product Specifications
CAS Number
[1316215-12-9]
Product Name Alternative
ACY241
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Citarinostat.html
Purity
99.55
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CN=C(N(C2=CC=CC=C2Cl)C3=CC=CC=C3)N=C1)NCCCCCCC(NO)=O
Molecular Formula
C24H26ClN5O3
Molecular Weight
467.95
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
HDAC1; HDAC2; HDAC3; HDAC6; HDAC7; HDAC8
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PRG2, ID (LPPR3, PHP2, PRG2, Lipid phosphate phosphatase-related protein type 3, PAP-2-like protein 2, Plasticity-related gene 2 protein)
PRG2, ID (LPPR3, PHP2, PRG2, Lipid phosphate phosphatase-related protein type 3, PAP-2-like protein 2, Plasticity-related gene 2 protein)
